• New Validated CTC Assays
  • Prostate → ARv7
  • Breast → HER2/ER
  • Immuno Oncology → PD-L1
Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics

News & Events

RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing
more →

RareCyte® expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit.
more →

RareCyte® launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis.
more →

Highlight

RareCyte expands its world-class liquid biopsy imaging and retrieval platform to support tissue workflows with the new CyteFinder II Instruments.

more →

RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.

more →

Pharma Programs

RareCyte Pharma Programs support pharma development through our expert product development teams. Our services span the range from RUO product development for pre-clinical and clinical research to IVD support for companion diagnostic co-development.

more →